Pub Date : 2021-07-02DOI: 10.2174/9789814998093121070005
J. Barbosa, Paula Teixeira
{"title":"Bioactive Substances as Anti-infective Strategies Against Clostridioides Difficile","authors":"J. Barbosa, Paula Teixeira","doi":"10.2174/9789814998093121070005","DOIUrl":"https://doi.org/10.2174/9789814998093121070005","url":null,"abstract":"","PeriodicalId":367372,"journal":{"name":"Frontiers in Clinical Drug Research: Anti-Infectives","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128662916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-02DOI: 10.2174/9789814998093121070007
A. R. Q. Gomes, K. Albuquerque, H. P. C. Brígido, Juliana Correa-Barbosa, M. Dolabela, S. Percário
{"title":"Development of Antimalarial and Antileishmanial Drugs from Amazonian Biodiversity","authors":"A. R. Q. Gomes, K. Albuquerque, H. P. C. Brígido, Juliana Correa-Barbosa, M. Dolabela, S. Percário","doi":"10.2174/9789814998093121070007","DOIUrl":"https://doi.org/10.2174/9789814998093121070007","url":null,"abstract":"","PeriodicalId":367372,"journal":{"name":"Frontiers in Clinical Drug Research: Anti-Infectives","volume":"59 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130577369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-02DOI: 10.2174/9789814998093121070006
Jhony Anacleto-Santos, Perla Y. López-Camacho, E. Vega-Ávila, R. Mondragón-Flores, Elba Carrasco-Ramírez, Norma Rivera Fernández
{"title":"Anti-Toxoplasma Drug Discovery and Natural Products: a Brief Overview","authors":"Jhony Anacleto-Santos, Perla Y. López-Camacho, E. Vega-Ávila, R. Mondragón-Flores, Elba Carrasco-Ramírez, Norma Rivera Fernández","doi":"10.2174/9789814998093121070006","DOIUrl":"https://doi.org/10.2174/9789814998093121070006","url":null,"abstract":"","PeriodicalId":367372,"journal":{"name":"Frontiers in Clinical Drug Research: Anti-Infectives","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126308810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-02DOI: 10.2174/9789814998093121070003
S. Evran, Ö. Uğurlu, E. Man, M. Gültan, C. Özyurt
Aptamers with target-specific binding properties have emerged as an alternative to antibodies. Nucleic acid aptamers are short single-stranded oligonucleotides that can fold into unique three-dimensional structures. Nucleic acid aptamers are selected from random libraries in vitro by using the SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technology. Likewise, peptide aptamers are short peptides that can be selected in vitro by using different strategies including phage display, ribosome display, or mRNA display. Aptamers are superior to antibodies with regard to ease of production, high stability, small size, and low cost. Therefore, aptamers find broad use in different biotechnological and therapeutic applications. Among them, aptamer use in virus detection and antiviral therapy is one of the attractive applications. The present Covid-19 pandemic and life-threatening viral infections reveal the need for rapid therapeutic solutions that can efficiently target viral mechanisms. In this respect, the chapter is mainly focused on aptamers with antiviral activity, as well as the use of aptamers in viral detection platforms. First, we summarize aptamer selection technologies that can be performed in vitro. Among them, we briefly explain ribosome display, mRNA display and SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technologies. Then, we review aptamers targeting viral proteins and viral invasion mechanisms. In addition, we give an overview of aptamers developed against viruses. We also discuss the major hurdles in aptamer use, as well as the strategies to improve the drug potential of aptamers.
具有目标特异性结合特性的适体已成为抗体的替代品。核酸适体是短单链寡核苷酸，可以折叠成独特的三维结构。利用SELEX (Systematic Evolution of Ligands by Exponential Enrichment)技术从体外随机文库中选择核酸适体。同样，肽适体是短肽，可以通过不同的策略在体外选择，包括噬菌体展示、核糖体展示或mRNA展示。适配体在易于生产、稳定性高、体积小、成本低等方面优于抗体。因此，适体在不同的生物技术和治疗应用中有着广泛的应用。其中，适体在病毒检测和抗病毒治疗中的应用是最具吸引力的应用之一。当前的Covid-19大流行和危及生命的病毒感染表明，需要能够有效靶向病毒机制的快速治疗解决方案。在这方面，本章主要关注具有抗病毒活性的适体，以及适体在病毒检测平台中的应用。首先，我们总结了可以在体外进行的适体选择技术。其中，简要介绍了核糖体展示、mRNA展示和SELEX (Systematic Evolution of Ligands by Exponential Enrichment)技术。然后，我们综述了靶向病毒蛋白的适体及其入侵机制。此外，我们还概述了针对病毒开发的适体。我们还讨论了适体使用的主要障碍，以及提高适体药物潜力的策略。
{"title":"Nucleic Acid and Peptide Aptamers as Potential Antiviral Drugs","authors":"S. Evran, Ö. Uğurlu, E. Man, M. Gültan, C. Özyurt","doi":"10.2174/9789814998093121070003","DOIUrl":"https://doi.org/10.2174/9789814998093121070003","url":null,"abstract":"Aptamers with target-specific binding properties have emerged as an alternative to antibodies. Nucleic acid aptamers are short single-stranded oligonucleotides that can fold into unique three-dimensional structures. Nucleic acid aptamers are selected from random libraries in vitro by using the SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technology. Likewise, peptide aptamers are short peptides that can be selected in vitro by using different strategies including phage display, ribosome display, or mRNA display. Aptamers are superior to antibodies with regard to ease of production, high stability, small size, and low cost. Therefore, aptamers find broad use in different biotechnological and therapeutic applications. Among them, aptamer use in virus detection and antiviral therapy is one of the attractive applications. The present Covid-19 pandemic and life-threatening viral infections reveal the need for rapid therapeutic solutions that can efficiently target viral mechanisms. In this respect, the chapter is mainly focused on aptamers with antiviral activity, as well as the use of aptamers in viral detection platforms. First, we summarize aptamer selection technologies that can be performed in vitro. Among them, we briefly explain ribosome display, mRNA display and SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technologies. Then, we review aptamers targeting viral proteins and viral invasion mechanisms. In addition, we give an overview of aptamers developed against viruses. We also discuss the major hurdles in aptamer use, as well as the strategies to improve the drug potential of aptamers.","PeriodicalId":367372,"journal":{"name":"Frontiers in Clinical Drug Research: Anti-Infectives","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123687672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-08-20DOI: 10.2174/9789811425745120060002
{"title":"List of Contributors","authors":"","doi":"10.2174/9789811425745120060002","DOIUrl":"https://doi.org/10.2174/9789811425745120060002","url":null,"abstract":"","PeriodicalId":367372,"journal":{"name":"Frontiers in Clinical Drug Research: Anti-Infectives","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131564341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-08-20DOI: 10.2174/97898114257451200601
{"title":"Frontiers in Clinical Drug Research: Anti-Infectives: Volume 6","authors":"","doi":"10.2174/97898114257451200601","DOIUrl":"https://doi.org/10.2174/97898114257451200601","url":null,"abstract":"","PeriodicalId":367372,"journal":{"name":"Frontiers in Clinical Drug Research: Anti-Infectives","volume":"36 13","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132836444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：